A significant drop in Cardiol Therapeutics' stock raises concerns among investors.
Cardiol Therapeutics Inc Class A saw its stock price fall sharply yesterday, down 6.86% to close at CA$2.58. This decline has left investors questioning the company's stability, especially with little news or market activity to explain the drop.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$234.52M
52W high
$3.23
52W low
$1.23
1W change
-19.25%
Beta
0.72
Analyst Price Targets
Based on analyst covering CRDL · as of Sep 17, 2026
Wall Street analysts forecast CRDL stock price to rise 354.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+354.5% Upside
Current Price
C$1.32
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
76.8%
Annualized
90-Day Vol
66.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.31
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.05 | C$1.57 – C$2.67 |
| 60 trading days | C$2.17 | C$1.49 – C$3.16 |
| 90 trading days | C$2.31 | C$1.46 – C$3.65 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Keep an eye on Cardiol's financial health and market sentiment, particularly given its recent stock performance and the absence of major announcements.
Stock fell 6.86% yesterday
Cardiol Therapeutics now has a market cap of CA$301 million, reflecting growing concerns about its future prospects.
Bull case
If Cardiol Therapeutics can effectively use its recent filings and participation in conferences to attract investment, it may bounce back from this downturn.
Bear case
Ongoing uncertainty and a lack of positive developments could further undermine investor confidence and lead to more declines.
Advertisement
Market Reaction to Cardiol's Performance
The decline in Cardiol Therapeutics' stock price highlights broader investor worries about the company's growth trajectory. With a market cap of CA$301 million, this significant drop signals a potential lack of confidence among investors. The absence of recent positive news may have intensified this sentiment.
Future Outlook for Cardiol Therapeutics
Looking ahead, Cardiol's recovery will depend on its strategic initiatives and how well it communicates its value to investors. The recent filing for a US$150 million preliminary base shelf prospectus could provide the capital needed for future projects, but the market will be watching closely to see how these plans develop.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
